1. Search Result
Search Result
Results for "

collagen 1

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

9

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113403

    Endogenous Metabolite Others
    Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .
    Pyridinoline
  • HY-E70005E

    MMP Others
    Collagenase, Type V is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type V breaksdown collagens1, 3, 5, 7, 8, 10, fibronectin, gelatin, aggrecann .

    Collagenase, Type V
  • HY-E70005A
    Collagenase, Type I
    2 Publications Verification

    EC 3.4.24.3

    MMP Others
    Collagenase, Type I is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type I breaks down collagens 1, 3, 7, 8, 10, gelatin, proteoglycans, aggrecan .

    Collagenase, Type I
  • HY-E70005B
    Collagenase, Type II
    2 Publications Verification

    MMP Others
    Collagenase, Type II is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type II breaksdown collagens1, 3, 5, 7, 8, 10, fibronectin, gelatin, aggrecann .

    Collagenase, Type II
  • HY-N1584R

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone (Standard)
  • HY-173235

    Galectin Cardiovascular Disease Inflammation/Immunology Cancer
    Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 12 nM and a Kd value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases .
    Galectin-3-IN-6
  • HY-N5061

    Others Cardiovascular Disease
    Rotundatin is useful in inhibition of the aggregation of platelets induced by arachidonic acid and collagen .
    Rotundatin
  • HY-P4812

    Biochemical Assay Reagents Metabolic Disease
    Prepro-von Willebrand factor (641-650) (bovine) is a fragment of Prepro-von Willebrand factor, which binds to type I collagen .
    Prepro-von Willebrand factor (641-650) (bovine)
  • HY-W738852

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Hydroxylysylpyridinoline-d6 is deuterium labeled Pyridinoline. Pyridinoline, a fluorescent material, is a bone resorption biomarker. Pyridinoline also is a type crosslink of collagen .
    Hydroxylysylpyridinoline-d6
  • HY-N1584AR

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone (hydrobromide) (Standard)
  • HY-N1584B
    Halofuginone hydrochloride
    5+ Cited Publications

    RU-19110 hydrochloride

    Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrochloride
  • HY-N1584BR

    Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrochloride) (Standard) is the analytical standard of Halofuginone (hydrochloride). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects [4] .
    Halofuginone (hydrochloride) (Standard)
  • HY-N1584
    Halofuginone
    Maximum Cited Publications
    11 Publications Verification

    RU-19110

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone
  • HY-N1584A
    Halofuginone hydrobromide
    Maximum Cited Publications
    11 Publications Verification

    RU-19110 hydrobromide

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide
  • HY-N1584C
    Halofuginone lactate
    Maximum Cited Publications
    11 Publications Verification

    RU-19110 lactate

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone lactate
  • HY-158225

    Col1MA

    MMP Others
    Methacrylated Type I collagen (Col1MA) is a methacrylated tissue engineering scaffold material that retains the basic properties of natural collagen . Methacrylated Type I collagen needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
    Application: cell culture, biological 3D printing, tissue engineering, etc.
    Methacrylated Type I collagen
  • HY-E70005C

    MMP Others
    Collagenase, Type III is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type III breaksdown collagens1, 4, 9, 10, 14, fibronectin, MMP-9, gelatin, plasminogen, aggrecan,perlecan osteonectin

    Collagenase, Type III
  • HY-115912

    Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
    GPVI antagonist 3
  • HY-N14932

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride A is a platelet aggregation inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride A
  • HY-N14934

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride C is a platelet aggregation inhibitor. Aggreceride C shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride C
  • HY-N14933

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Aggreceride B is a platelet aggregation inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
    Aggreceride B
  • HY-169940

    HDAC Inflammation/Immunology
    Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC50 value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .
    Fibrostat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: